Are we over-estimating the effectiveness of dementia therapies? A Systematic Review of the use of Last-Observation-Carried-Forward in Dementia Drug Studies.

Frank J. Molnar MSc MDCM FRCPC1,2,3

Malcolm Man-Son-Hing MSc MD FRCPC1,2,3

Brian Hutton BSc, MSc 1

Dean Fergusson MHA, PhD1,4,5

1Clinical Epidemiology Program, the University of Ottawa Health Research Institute, 2Élisabeth-Bruyère Research Institute, Ottawa; 3Division of Geriatric Medicine, Department of Internal Medicine, University of Ottawa; 4Clinical Trials Research Group, Biomedical Ethics Unit, McGill University; 5Department of Medicine, University of Ottawa.

Corresponding Author:

Dr. F. Molnar

Director of Research

University of Ottawa Division of Geriatric Medicine

The Ottawa Hospital, Civic Campus

1053 Carling Ave, Ottawa Ontario, Canada K1Y 4E9

Telephone: (613) 798-5555 ext 16486

Fax (613) 761-5334

email: [fmolnar@ottawahospital.on.ca](mailto:fmolnar@ottawahospital.on.ca)

Brian Hutton

Biostatistician

Research Coordinator, Age of Blood in Premature Infants **(ARIPI)** Study

Ottawa Health Research Institute

Ottawa University Center for Transfusion Research

**E-mail:** [bhutton@ohri.ca](mailto:bhutton@ohri.ca)

**Phone:**  (613) 737-8122

Ottawa Hospital

501 Smyth Road

Ottawa, Ontario

K1H 8L6

Malcolm Man-Son-Hing

University of Ottawa Division of Geriatric Medicine

The Ottawa Hospital, Civic Campus

1053 Carling Ave, Ottawa Ontario, Canada K1Y 4E9

Telephone: (613) 798-5555 ext 16486

Fax (613) 761-5334

email: [mhing@ohri.on.ca](mailto:mhing@ohri.on.ca)

Dean A. Fergusson, MHA, PhD

Director, The CEP Methods Centre, The Ottawa Hospital

Associate Director, Clinical Epidemiology Program

Scientist, Ottawa Health Research Institute

Phone #: 613-737-8899 Ext. 7-9216

Fax #: 613-739-6266

[dafergusson@ottawahospital.on.ca](mailto:dafergusson@ottawahospital.on.ca)

# ABSTRACT

*Objective*: To examine the use of intent-to-treat (ITT) imputation of missing data techniques, such as Last-Observation-Carried-Forward, employed in cholinesterase inhibitor and memantine randomized-controlled trials (RCTs) in Alzheimer disease, Vascular dementia, Mixed dementia and Mild Cognitive Impairment.

*Design*: Systematic review of analytic methodology.

*Data Sources*: Systematic electronic search of Medline and Cochrane’s RCT Register, supplemented by hand search of the reference lists of selected articles, meta-analyses and review articles.

*Review Methods*: Two reviewers independently reviewed selected RCT reports; extracted data using standardized forms and performed quality assessments using the Jadad scale (+ Schultz criteria). These reviewers then met to review discrepancies in extracted data, and to resolve these via a modified Delphi technique.

*Results*: Of the 57 studies selected, 12 did not report the results of ITT analyses and 35 employed Last-Observation-Carried-Forward as the only form of ITT analysis (with 24 of these studies reporting conditions that could promote bias favoring the drug under study in Last-Observation-Carried-Forward analyses).

*Conclusions*: The findings suggest that the published results of some dementia drug RCTs may be inaccurate (i.e. exaggerated effectiveness) or potentially invalid (i.e. false positive results). RCTs that either did not report the results of ITT analyses or employed Last-Observation-Carried-Forward while also demonstrating conditions that could introduce bias in favor of the drugs under study (e.g. greater dropout in treatment groups) should be reanalyzed to verify their results.

The potential problem uncovered may represent the ‘tip of the iceberg’. Systematic reviews of the use of Last-Observation-Carried-Forward in other areas of research involving chronic progressive disorders (e.g. Osteoporosis, Parkinson’s disease, Lewy Body disease, Stroke, Multiple Sclerosis, COPD, Congestive Heart Failure, Diabetes, Chronic Renal Insufficiency, AIDS etc.) are encouraged.

Given the potentially enormous scope of this problem, the CONSORT group ([www.consort-statement.org](http://www.consort-statement.org/) ) should consider incorporating additional guidelines regarding appropriate analyses for studies of medications used to treat chronic progressive disorders. Licensing authorities (e.g. U.S. Food & Drug Administration, European Agency for the Evaluation of Medicinal Products, Health Canada) should review the suitability of Last-Observation-Carried-Forward in drug research in chronic progressive diseases.

Key words: Alzheimer’s disease, dementia, clinical trials, dropout, withdrawal, intent-to-treat, missing data

Are we over-estimating the effectiveness of dementia therapies? A Systematic Review of the use of Last-Observation-Carried-Forward in Dementia Drug Studies.

# INTRODUCTION:

Worldwide it is estimated that 24.3 million people suffer from dementia and that the annual costs for Alzheimer’s disease (1996 $US dollars) range as high as $155 billion in the US.1,2 It has been argued that one potential approach to decreasing the negative impact on patients, families and societies may be the optimal use of medications to treat dementia.2

Since its introduction in the 1960s, the principle of intention-to-treat (ITT), the inclusion of all patients in the analysis according to the group determined at randomization, has become the accepted standard for the analysis of controlled clinical trials.3  The strength of ITT is that it promotes balance between treatment groups for both known and unknown confounders, thereby preserving the benefits of randomization. In order for ITT approaches to analyze all patients randomized, including dropouts, several methods to impute missing data have been developed.3-10

A commonly employed technique to impute missing data is Last-Observation-Carried-Forward, also known as ‘endpoint analysis’. Last-Observation-Carried-Forward replaces subjects’ missing outcomes with the last available measurement and requires that two basic conditions be met: [1] that the subjects’ responses would have been constant (i.e. stable) from the last observed value (i.e. point of dropout) to the endpoint of the trial rather than declining or improving further, and [2] that missing values are ‘missing completely at random’ (i.e. that the probability of dropout is not related in any way to variables such as disease severity, symptoms, group assignment or drug side-effects).5-7

Since 1998, researchers have expressed concern that the use of Last-Observation-Carried-Forward in dementia drug trials contravenes both assumptions and, hence, risks generating biased results.2,11-21 It has been pointed out that since progression is the hallmark of dementia,22,23 the first condition of stable values from the point of dropout to the end of a study cannot be guaranteed.3,9,10

It has also been pointed out that Last-Observation-Carried-Forward ignores the trajectory of a patient’s clinical progress (i.e. whether the subject was improving or getting worse at the time of dropout).8 It freezes outcome values at the last observation, thereby creating an apparent stabilization of disease and/or function in dropouts (Figure 1). Based on this effect, authors have highlighted three contraindications to the use of Last-Observation-Carried-Forward - factors that indicate the second condition (e.g. values are missing completely at random) has been breeched and that can bias results in favor of the drug under study relative to the placebo: [1] greater dropout rates in the treatment group, [2] earlier dropouts in the treatment group, and [3] more rapid progressors in the treatment dropout group.3,4,9,10,11 These conditions result in more treatment group dropouts having their decline artificially frozen at an earlier stage of disease thereby inflating the measured efficacy of the drug under study. Researchers have not raised similar concerns regarding other imputation techniques.

It remains unclear how concerned we should be regarding the limitations of Last-Observation-Carried-Forward. If a drug study clearly ruled out or minimized the effect of the abovementioned contraindications or if Last-Observation-Carried-Forward were verified by a sensitivity analysis that included other ITT imputation of missing data techniques, then there would seem to be little to worry about. Conversely, if contraindications to the use of Last-Observation-Carried-Forward are present in a trial and Last-Observation-Carried-Forward based results are not verified by other ITT imputation of missing data techniques in a sensitivity analysis, then we should be more concerned regarding potential bias in such a study.

To better understand how significant these concerns might be in dementia research we examined not only the prevalence of use of Last-Observation-Carried-Forward but also the frequency with which the above contraindications were present in randomized trials employing Last-Observation-Carried-Forward to estimate the efficacy of cholinesterase inhibitors and memantine in the treatment of Alzheimer disease, Vascular dementia, Mixed dementia and Mild Cognitive Impairment.

METHODS:

This systematic review was conducted in accordance with the QUOROM guidelines 24 (adapted for a methodological systematic review).

**Identification of Studies:**

An electronic literature search of Medline and the Cochrane Register of Controlled Trials from 1989 to February 2008 was performed using the OVID search interface. The search strategy included the following terms, and the Medline search was augmented by the use of the Dickersin filter for identification of randomized controlled trials: *dementia, Alzheimer, vascular dementia, mixed dementia, donepezil, Aricept, rivastigmine, Exelon, galantamine, Reminyl, memantine, Ebixa, cholinesterase inhibitor*. This electronic search was supplemented by hand searching of the reference lists of selected articles, meta-analyses and review articles.

Eligibility Criteria:

Double-blinded, randomized controlled trials of cholinesterase inhibitors or memantine examining progressive symptoms (e.g. cognition, function) in Alzheimer disease, Vascular dementia, Mixed dementia or Mild Cognitive Impairment employing DSM (Diagnostic and Statistical Manual of Mental Disorders)22 or NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke – Alzheimer’s Disease and Related Disorders Association)23 criteria for Alzheimer’s disease or NINDS-AIREN (National Institute of Neurological Disorders and Stroke – Association Internationale pour la Recherche et l’Enseignement en Neurosciences) criteria for Vascular Dementia were eligible for this review. Trials of cholinesterase inhibitors not currently licensed in Canada (tacrine, metrifonate) were not reviewed. The systematic review was restricted to studies with full trial reports published in English language peer-reviewed journals. The diagnostic criteria for Mild Cognitive Impairment were not specified, as they were still in development when the relevant studies were being published.

Open label studies, reviews, meta-analyses, commentaries, editorials, studies of pooled data from previous studies, tolerability and safety studies were not included. Subgroup analyses, secondary or retrospective analyses were also excluded.

Data Collection:

Data collected included publication details, investigative site locations, funding, drug comparators, drug doses, diagnostic criteria employed, type(s) of analysis employed, discussion of the limitations of the forms of analysis employed, dropout characteristics (e.g. number, timing, patient characteristics, reasons for dropout), , contraindications to the use of Last-Observation-Carried-Forward, and the results of each primary and secondary outcome measure employed.

Two certified specialists in Geriatric Medicine with clinical expertise in dementia, with formal research methodological training and with recognized expertise in the review of dementia drug trials independently extracted data from all included studies. The two reviewers resolved discrepancies in extracted data using a modified Delphi technique.

Quality Assessment of Included Trials:

Study report quality was assessed using the validated, 3-item Jadad scale (with the addition of the 1 point Schultz criteria).25 This scale assigns points for randomization (0-2 points), double-blinding (0-2 points) and account for withdrawals (1 point).

RESULTS:

Of the 1146 articles identified by the search strategies, 191 were selected for full text review. Of these, 57 articles met the eligibility criteria for systematic review (Figure 2).2,14,20,21,26-79

**Trial Characteristics (Tables 1 & 2):**

Details of the 57 included trials are provided in Tables 1 and 2. Forty-five studies enrolled patients with Alzheimer disease (21 donepezil, 11 rivastigmine [1was a donepezil-rivastigmine comparison study], 7 galantamine, 6 memantine), 8 enrolled patients with vascular dementia or mixed dementia (3 donepezil, 3 galantamine, 2 memantine) and 4 enrolled patients with MCI (2 donepezil, 1 rivastigmine, 1 galantamine).

Forty trials explicitly indicated they were funded by industry, 6 implied industry funding (the authors were industry employees but the source of funding was not explicitly stated), 3 were funded by industry in partnership with public funders and four studies reported being entirely publicly funded (Table 1). The source of funding for 4 studies could not be determined.

All 57 study reports were rated as demonstrating high quality methodology with a Jadad / Schultz score ≥ 3 ((Table 1).

**Reporting of Dropouts (Tables 3 & 4):**

Ten studies (18%) discussed potential bias secondary to dropouts (Table 3).

Dropouts were described in 94% of cholinesterase inhibitor studies and 100% of memantine trials (Table 4). The descriptions were often incomplete with respect to timing and reasons for dropout. Seven of the 49 cholinesterase inhibitor trials (14%) and none of the memantine trials reported data on timing of dropouts. The reasons for dropout were often difficult to discern, as many were described as ‘adverse events’ that might be due to drug side effects, but were not reported as such. Cholinesterase inhibitor studies were more likely to demonstrate greater dropout in the treatment group (73% of studies) compared to memantine studies (25% of studies). Table 4 demonstrates that when cholinesterase inhibitor studies were combined, there was a higher dropout rate in the treatment group (23.3%) than in the control group (16.8%). When memantine trials were combined the opposite pattern was noted with fewer dropouts in the treatment group (14.6%) than in the control group (18.5%).

Types of non-ITT Analyses Conducted (Tables 2 & 3):

The most common non-ITT analysis (employed in 35 trials) was Observed Case analysis (Tables 2 & 3). Other forms of non-ITT analysis included Fully Evaluable Population analysis (FEP), Treatment Per Protocol analysis (TPP) and Completer analysis (CA). These were rarely described as non-ITT analyses.

**Types of ITT Analyses Conducted (Tables 2 & 3):**

The results demonstrate that 12 (21%) of the 57 studies did not identify the type of ITT analysis performed or performed only non-ITT analysis. Of the remaining 45 studies that did perform an identifiable form of ITT analysis, 42 (93%) employed Last-Observation-Carried-Forward. Thirty-five of the trials that performed ITT analysis (78 %) relied on Last-Observation-Carried-Forward as the only form of ITT analysis.

Ten of the 57 studies (17.5%) reported employing ITT techniques other than Last-Observation-Carried-Forward (Tables 2 and 3). Breaking this down by drug class demonstrates that 6 of 49 cholinesterase studies (12%) and 4 of 8 memantine studies (50%) employed ITT techniques other than Last-Observation-Carried-Forward. The alternate ITT imputation of missing data techniques included: replacement of missing values with the mean changes observed in the placebo group,42, 58  time response relationship for ADAScog/11 analyzed using generalized linear modeling,50, 52 mixed effects modeling,56, 63 mixed models repeated measures (MMRM),78,79 replacement of missing data with worst ranks,57 and sensitivity analyses consisting of a number of simulations.68

Eight of these 10 studies performed both Last-Observation-Carried-Forward and a confirmatory ITT technique other than Last-Observation-Carried-Forward. Put differently, of the 42 studies that employed Last-Observation-Carried-Forward, only 8 reported performing another type of ITT analysis. Three of these 8 studies did not comment on the results of the alternate non- Last-Observation-Carried-Forward analysis. Of the 5 studies that commented on the results of the alternate ITT analysis, 4 did not report the values of the outcomes calculated by the alternate ITT analysis but did indicate that the direction of results was unchanged. This would indicate that the direction of the findings of the 6 positive outcomes in these 4 studies was unchanged when Last-Observation-Carried-Forward analysis was verified by another ITT analysis (i.e. no false positive findings were generated by Last-Observation-Carried-Forward).

Only 1 study verified the point estimates of outcomes measuring drug efficacy generated by Last-Observation-Carried-Forward with point estimates of an alternate form of ITT analysis.42 The study verified the values of 3 positive outcomes.

Contraindications to the use of Last-Observation-Carried-Forward as the only form of ITT analysis:

Of the 35 studies employing Last-Observation-Carried-Forward as the only form of ITT analysis, 23 (66 %) explicitly demonstrated contraindications (factors that could introduce bias) to the use of Last-Observation-Carried-Forward.It was unclear if the remaining 12 studies were free of contraindications as most studies failed to report adequate data regarding the timing and severity of disease of dropouts to permit a precise estimate of the number of contraindications to the use of Last-Observation-Carried-Forward. Consequently, Table 2 provides a range of potential contraindications to the use of Last-Observation-Carried-Forward for each study. Seven trials (12%) discussed the limitations of Last-Observation-Carried-Forward or non-ITT approaches (Table 3).

DISCUSSION:

This study set out to determine whether the coexistence of Last-Observation-Carried-Forward and contraindications to the use of this form of analysis (i.e. conditions that would increase the probability of bias) were relatively infrequent occurrences of minor significance or whether these were highly prevalent occurrences suggesting the need for further study to rule out the possibility of widespread bias in this field of research. The study also examined whether confirmatory ITT analyses (e.g. Sensitivity Analyses) were published to rule out the possibility of ‘*Last-Observation-Carried-Forward bias’*.

The results demonstrate that Last-Observation-Carried-Forward has been the primary approach employed for imputation of missing values in ITT analyses in dementia and MCI drug trials. Despite previously published cautions that this form of analysis may introduce bias into research on dementia, the results are rarely verified by other forms of ITT analysis. This is particularly concerning in cholinesterase inhibitor research as most of the cholinesterase inhibitor studies reviewed violated the conditions required for valid (i.e. unbiased) Last-Observation-Carried-Forward analyses (Table 2): [1] the assumption that missing values are ‘missing completely at random’ is unlikely given the frequently reported gastrointestinal side-effects of the cholinesterase inhibitors; [2] differential dropout (e.g. greater dropout in the treatment group) is widely prevalent in cholinesterase inhibitor research; and [3] given the fact that progression is the hallmark of dementia and is incorporated into the definitions of dementia22 and of Alzheimer disease23, the assumption that subjects’ outcome measures would remain constant from the time of dropout until completion of the trial (rather than declining further) is not guaranteed to be correct. The latter concern is supported by the fact that the reviewed studies often include graphs demonstrating continued decline in outcome measures throughout the study. Conditions that may lead to bias in favor of the drugs under study when employing Last-Observation-Carried-Forward analysis are frequently present in cholinesterase inhibitor studies that rely on Last-Observation-Carried-Forward as the sole form of ITT analysis. Due to lack of data on timing of dropouts and severity of disease in dropouts, our results may underestimate the true extent of the problem uncovered. Until completion and reporting of studies that verify the point estimates of drug efficacy of publications that relied on Last-Observation-Carried-Forward as the sole form of ITT analysis while also demonstrating conditions that would promote bias (e.g. greater dropout in the treatment group), the point estimates of efficacy of such studies should be interpreted with caution.

Memantine appears to have fewer side effects relative to cholinesterase inhibitors and differential dropout is less of an issue in memantine studies. In fact, the greater dropouts in the control groups could result in Last-Observation-Carried-Forward biasing the results against this drug and underestimating its’ true efficacy. It is therefore possible that, when compared to cholinesterase inhibitor research, memantine studies may be disadvantaged by the use of Last-Observation-Carried-Forward.

The concern that Last-Observation-Carried-Forward might introduce bias can be addressed by sensitivity analyses that demonstrate similar outcomes when other forms of ITT analysis are employed. Only one study42 verified the point estimates of efficacy calculated by Last-Observation-Carried-Forward with an alternate ITT analysis. These are only 3 positive outcomes out of the hundreds of outcomes reported in the studies reviewed. Regrettably, there is insufficient published information to assure us that Last-Observation-Carried-Forward has not introduced bias in other dementia drug studies. Rather, there is significant evidence that the risk that it has introduced bias is fairly high, particularly in cholinesterase inhibitor research where drug side effects resulting in greater treatment group dropouts are common.

The argument that results based on Last-Observation-Carried-Forward are correct because they are supported by the results of alternate analyses (e.g. observed case analysis, completer analysis, fully-evaluable population analysis, or treated per protocol analysis) is questionable if not completely invalid. These techniques do not impute missing data, but rather exclude subjects without data from analysis. Since they do not analyze all randomized patients, they are not ITT analyses. Many will be systematically biased in the same direction as Last-Observation-Carried-Forward (i.e. in favor of the group with greater, earlier and/or more severely affected dropouts), and do not represent valid confirmatory sensitivity analyses. The biases inherent in these non-ITT techniques have been highlighted by the International Conference on Harmonisation Tripartite Guideline,80 by the European Agency for the Evaluation of Medicinal Products (EMEA)14 as well as by a number of authors.15,53,67,81

Given the above, it is difficult to justify the ongoing reliance on Last-Observation-Carried-Forward as the sole form of ITT analysis in dementia studies. Other forms of ITT analysis that do not treat dropouts artificially by freezing values at the point of dropout, but rather model for expected natural decline in dropouts, would not cost anything to perform and to publish (either as the primary analysis or as a sensitivity analysis). The modeling can be as simple as using the rate of decline noted in the control group and applying it to all dropouts. More complex modeling procedures are available in standard statistical programs. More appropriate forms of analysis have been employed in the field of dementia research. 42, 50, 52,56-58, 68, 78, 79 Petersen’s MCI study68 may serve as a model for future research, as it employed both modelling for dropouts and sensitivity analyses of the effect of various modelling assumptions and approaches.

By demonstrating the reliance on Last-Observation-Carried-Forward as the only form of ITT analysis in a high percentage of studies that also demonstrate factors that will promote bias when Last-Observation-Carried-Forward is used (e.g. greater dropouts in the treatment group), this study provides further validation of the concerns previously raised regarding the use of Last-Observation-Carried-Forward in dementia drug trials.2, 3, 9 – 21 The results of this study, therefore, provide a strong rationale for the reanalysis of previously published dementia studies that relied solely on Last-Observation-Carried-Forward as the only form of ITT analysis (particularly for those demonstrating greater dropout in treatment groups) and for studies that did not publish any identifiable ITT analyses.

Verifying Last-Observation-Carried-Forward based results would require individual patient data that, unfortunately, are not in the public domain. Therefore this study cannot quantify the magnitude of the effect of the use of Last-Observation-Carried-Forward on trial results but is restricted to highlighting the prevalence and potential seriousness of the problem.

Given the fact that the concerns regarding the use of Last-Observation-Carried-Forward in dementia studies predate most of the trials reviewed and that the primary study data required for reanalysis of these studies is not in the public domain, the onus is therefore on the investigators who have published these trials to disprove the possibility that Last-Observation-Carried-Forward or non-ITT analyses have introduced bias into their trials. To do so they would need to re-analyze their studies using ITT modeling techniques that anticipate the trajectory of disease in dropouts. In order to insure the robustness of the findings based on such modeling, sensitivity analyses employing various types of modeling and varying data employed by models should be presented, as was done in Petersen’s MCI study.68 Meta-analyses that did not employ modelling for decline in individual dropouts should also be re-analysed in a similar fashion, and such an approach should be adopted by future RCTs in dementia research.

These results are meaningful in day-to-day clinical care. Without accurate analyses, physicians cannot optimally counsel patients and families, patients and families cannot provide truly informed consent when making treatment decisions, accurate meta-analyses and pharmacoeconomic studies cannot be performed, and we cannot make reliable statements regarding whether trial results truly cross thresholds of clinical significance. Continued reliance on Last-Observation-Carried-Forward and non-ITT analyses may result in more toxic therapies, with greater and earlier dropout, being favored over less toxic therapies. This situation may already be occurring, as the greater dropout rate in treatment groups in cholinesterase inhibitor trials vs. greater dropout in the control groups in memantine studies (Table 4) may bias results in favor of cholinesterase inhibitors relative to memantine (thereby placing memantine at a relative disadvantage).

While there is a preponderance of evidence suggesting the drugs studied have some degree of positive effect in some patients, the high prevalence of the potential source of bias uncovered in this study suggests that we cannot be confident regarding the accuracy of point estimates of efficacy of many of the studies reviewed. We may not know how effective these drugs truly are. Without confirmatory ITT analyses, the worst-case scenario of false positive trials cannot be confidently excluded.

CONCLUSIONS:

The findings of this study are of major significance. The majority of the studies reviewed (38/57 = 66%) either did not report the results of an ITT analysis (12/57 = 21%), did not verify the results of Last-Observation-Carried-Forward when conditions that could introduce bias in favor of the study drug existed (23/57 = 40%), or did not comment on the results of alternate ITT analyses performed (3/57 = 5%). Furthermore, due to lack of data on timing of dropouts and severity of disease in dropouts, these results may underestimate the true extent of the problem uncovered.

It is highly unlikely that, given the findings of this study, the point estimates of some of the hundreds of positive outcomes generated in the reviewed trials that used Last-Observation-Carried-Forward have not been altered in some way. The question is likely not ‘*has bias been introduced’*, but rather ‘*how many outcomes have been biased*’ and ‘*to what degree have they been biased*’.

Given the enormous prevalence and cost of dementia, its severe impact on patients and families, and the associated rapidly escalating drug costs that are straining the resources of public health care systems, the possibility that the use of Last-Observation-Carried-Forward may have introduced bias into research on dementia therapies is a serious concern that needs to be ruled out or, if found to be true, should be corrected.

We have come a long way in terms of improving the methodology of dementia trials by selecting more appropriate outcome measures, study designs and sample sizes. The results of this study indicate that the research community should now take the next step in the ongoing evolution of dementia RCT methodology by focusing on the analytic approaches employed in these trials.

Scientists in other areas of research involving chronic progressive disorders (e.g. Osteoporosis, Parkinson’s disease, Lewy Body disease, Stroke, Multiple Sclerosis, COPD, Congestive Heart Failure, DM, Chronic Renal Insufficiency, AIDS etc.) are encouraged to perform similar reviews to examine the use of Last-Observation-Carried-Forward or non-ITT techniques in these highly prevalent and costly conditions.

Given the potentially enormous scope of this problem, the CONSORT group ([www.consort-statement.org](http://www.consort-statement.org/) ) should consider incorporating additional guidelines regarding appropriate analyses for studies of medications used to treat chronic progressive disorders. Journal editors, funding agencies, ethics review boards and drug formulary committees would then be able to request that such CONSORT recommendations be employedin future studies of dementia and other chronic progressive disorders.

Continued reliance on Last-Observation-Carried-Forward provides no benefits while creating unnecessary risk of generating biased results that will tend to favor more toxic therapies. Consequently, it is recommended that licensing agencies (e.g. US Food and Drug Administration, European Agency for the Evaluation of Medicinal Products, Health Canada etc.) review this situation in order to determine whether they should continue to accept Last-Observation-Carried-Forward analyses in research on dementias and other chronic progressive conditions.

ACKNOWLEDGEMENTS, FUNDING, CONFLICTS OF INTEREST, COMPETING INTERESTS:

None of the authors is aware of any actual, potential or perceived conflict of interests with respect to this publication. None of the authors has received financial support from private industry to perform this research. All authors were involved in the design, analysis, interpretation of data, and the preparation of this manuscript. Ethics approval was not required for this systematic review of trial methodology.

The Corresponding Author and guarantor (FJM) has had full access to all the data in the study and had final responsibility for the decision to submit for publication.

The authors would like to thank Judy Willoughby for her support in preparing this transcript as well as Emmanuel Nkansah for his assistance in searching the literature.

REFERENCES:

1. Ferri CP, Prince M, Brayne C et al. Global prevalence of dementia: a Delphi consensus study. The Lancet 2005; 366: 2112-2117
2. Wimo A, Winblad B, Stőffler A et al. Resource Utilization and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer’s Disease. Pharmacoeconomics 2003; 21(5): 327 – 340.
3. Unnebrink K, Windeler J. Intention-to-treat: methods for dealing with missing values in clinical trials of progressively deteriorating diseases. Statistics in Medicine 2001; 20: 3931 – 3946.
4. Engels JM, Diehr P. Imputation of missing longitudinal data: comparison of methods. Journal of Clinical Epidemiology 2003; 56: 968 – 976.
5. Gadbury GL, Coffey CS and Allison DB. Modern statistical methods for handling missing repeated measurements in obesity trial data: beyond LOCF. Obesity Reviews 2003; 4: 175 – 184.
6. Mallinckrodt CH, Clark WS, Carroll RJ and Molenberghs G. Assessing Response Profiles from Incomplete Longitudinal Clinical Trial Data Under Regulatory Considerations. Journal of Biopharmaceutical Statistics 2003; 13 (2): 179 – 190.
7. Mallinckrodt CH, Clark WS, and David SR. Accounting for dropout bias using mixed-effects models. Journal of Biopharmaceutical Statistics 2001; 11: 9 – 21.
8. Streiner DL. The Case of the Missing Data: methods of Dealing With Dropouts and Other Research Vagaries. Can J Psychiatry 2002; 47: 68 – 75.
9. Galasko D, Edland SD, Morris JC et al. The Consortium to establish a Registry for Azlheimer’s Disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer’s Disease followed over 3 years. Neurology 1995; 45: 1451-1455.
10. Meyer K, Windler J. Intention-to-treat in progressively deteriorating diseases: should the last observation be carried forward? Journal of Epidemiology and Biostatistics 1998; 3(2): 199 – 208.
11. Mallinckrodt CH, Sanger TM, Dubė S et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry 2003; 53: 754 – 760.
12. Rogers SL, Doody RS, Mohs RC et al. Donepezil Improves Cognition and Global Function in Alzheimer Disease; A 15 Week, Double-blind, Placebo-Controlled Study. Arch Intern Med 1998; 158: 1021 – 1031.
13. Aisen PS, Davis KL, Berg JD et al. A randomized controlled trial of prednisone in Alzheimer’s disease. Neurology 2000; 54(3): 588 – 592.
14. Committee For Proprietary Medicinal Products (CPMP). Points to consider on missing data. London, 2001: The European Agency for the Evaluation of medicinal products (EMEA), 2001. [www.emea.eu.int](http://www.emea.eu.int/)
15. Hills R, Gray R, Stowe R. Drop-out bias undermines findings of improved functionality with cholinesterase inhibitors. Neurobiol Aging 2002; 23 (suppl 1): S89.
16. Lanctột KL, Herrmann N, Yau KK et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a meta-analysis. CMAJ 2003; 169(6): 557 – 564.
17. Aisen PS, Schafer KA, Grundman M et al. Effects of Refocoxib or Naproxen vs. Placebo on Alzheimer Disease Progression: a Randomized Controlled Trial. JAMA 2003; 289(21): 2819 – 2826.
18. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105 – 2115.
19. Bullock R, Touchon J, Bergman H et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Current Medical Research and Opinions 2005; 21(8): 1317 – 1327.
20. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt H-P et al. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. BMJ 2005; 331: 321 – 327.
21. Hogan DB. Donepezil for severe Alzheimer’s disease. Lancet 2006; 367: 1031 – 1032.
22. Diagnostic and statistical manual of mental disorders, 4th ed.: DSM-IV. Washington D.C.: American Psychiatric Association, 1994
23. McKhann G, Drachman D, Folstein M, et al.: Clinical diagnosis of Alzheimer’s disease. Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939 – 944.
24. Clarke M. The QUORUM Statement. Lancet. 2000; 355(9205): 756 – 757.
25. Jadad AR, Moore RA, Carroll D et al. Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary? Control Clin Trials. 1996; 17:1–12.
26. Rogers SL, Friedhoff LT, and the Donepezil Study group. The Efficacy and Safety of Donepezil in Patients with Azlheimer’s Disease: results of a US Multicentre, randomized, Double-Blind, Placebo-Controlled Trials. Dementia 1996; 7: 293 – 303.
27. Rogers SL, Farlow MR, Doody RS. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998; 50(1): 136 – 145.
28. Burns A, Rossor M, Hecker J et al. The effects of donepezil in Alzheimer’s disease – results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237 – 244.
29. Greenberg SM, Tennis MK, Brown LB et al. Donepezil Therapy in Clinical Practice: a Randomized Crossover Study. Arch Neurol 2000; 57: 94 – 99.
30. Homma A, Takeda M, Imai Y et al. Clinical Efficacy and Safety of Donepezil on Cognitive and Global Function in Patients with Alzheimer’s Disease. Dement Geriatr Cogn Disord 2000; 11: 299 – 313.
31. Feldman H, Guathier S, Hecker J et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57: 613 – 620.
32. Mohs RC, Doody RS, Morris JC et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481 – 488.
33. Tariot PN, Cummings JL, Katz IR et al. A Randomized, Double-Blind, Placebo-Controlled study of the Efficacy and Safety of Donepezil in Patients with Alzheimer’s Disease in the Nursing Home setting. JAGS 2001; 49: 1590 – 1599.
34. Thomas A, Iacono D, Bonanni L et al. Donepezil, Rivastigmine, and Vitamin E in Alzheimer Disease: A Combined P300 Event-related Potentials / neuropsychologic evaluation over 6 Months. Clinical Neuropharmacology 2001; 24(1): 31 – 42.
35. Winblad B, Engedal K, Soininen H et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489 – 495.
36. Krishnan KRR, Charles HC, Doraiswamy PM et al. Randomized, Placebo-Controled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer’s Disease. Am J Psychiatry 2003; 160: 3003 – 2011.
37. Tune L, Tiseo PJ, Ieni J et al. Donepezil HCl (E2020) Maintains Functional Brain Activity in Patients With Alzheimer Disease: Results of a 24-Week, Double-Blind, Placebo-Controled Study. Am J Geriatr Psychiatry 2003; 11: 169 – 177.
38. Holmes C, Wilkinson D, Dean C et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63: 214 – 219.
39. dos Santos Moraes WA, Poyares DR, Guilleminault C et al. The Effect of Donepezil on Sleep and REM Sleep EEG in Patients with Alzheimer Disease: A Double-Blind Placebo-Controlled Study. Sleep 2006 29(2): 199 – 205.
40. Seltzer B, Zolnouni P, Nunez M et al. Efficacy of Donepezil in Early-Stage Alzheimer Disease. Arch Neurol 2004; 61: 1852 – 1856.
41. Johannsen P, Salmon E, Hampel H et al. Assessing Therapeutic Efficacy in a Progressive Disease: A Study of Donepezil in Alzheimer’s Disease. CNS Drugs 2006; 20(4): 311 – 325.
42. Winblad B, Kilander L, Eriksson S et al. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367: 1057 – 1065.
43. Agid Y, Dubois B, Anand R et al. Efficacy and Tolerability of Rivastigmine in Patients With Dementia of the Alzheimer Type. Current Therapeutic Research 1998; 59(12): 837 – 845.
44. Corey-Bloom J, Anand R, Veach J et al. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. International Journal of Geriatric Psychopharmacology 1998; 1: 55 – 65.
45. Forette F, Anand R, Gharabawi G. A phase II study in patients with Alzheimer’s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). European Journal of Neurology 1999; 6: 423 – 429.
46. Rösler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomized controlled trial. BMJ 1999; 318: 633 – 640.
47. Kumar V, Anand R, Messina J et al. An efficacy and safety analysis of Exelon in Alzheimer’s disease patients with concurrent vascular risk factors. European Journal of Neurology 2000; 7: 159 – 169.
48. Doraiswamy PM, Krishnan KRR, Anand R et al. Long-term effects of rivastigmine in moderately severe Alzheimer’s disease: Does early initiation of therapy offer sustained benefits? Progress in Neuro-Psychopharmacology and Biological Psychiatry 2002; 26: 705 – 712.
49. Karaman Y, Erdoğan F, Kőseoğlu E et al. A 12-Month Study of the Efficacy of Rivastigmine in Patients with Advanced Moderate Alzheimer’s Disease. Dement Geriatr Cogn Disord 2005; 19: 51 – 56.
50. Raskind MA, Peskind ER, Wessel T et al. Galantamine in AD : a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261 – 2268.
51. Tariot PN, Solomon PR, Morris JC et al. A 5-month, randomized placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269 – 2276.
52. Wilcock GK, Lilienfeld S, Gaens. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomized controlled trial. BMJ 2000; 321: 1 – 7.
53. Rockwood K, Mintzer J, Truyen L et al. Effects of a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled trial. J Neurol Neurosurg Psychaitry 2001; 71 : 589 – 595.
54. Wilkinson D, Murray J, the Galantamine Research group. Galantamine: a randomised, double-blind, dose comparison in patients with Alzheimer’s disease. Int j Geriatr Psychiatry 2001; 16: 852 – 857.
55. Brodaty H, Corey-Bloom J, Potocnik FCV et al. Galantamine Prolonged-release Formulation in the Treatment of Mild to Moderate Alzheimer’s Disease. Dement Geriatr Cogn Disord 2005; 20: 120 – 132.
56. Rockwood K, Fay S, Song X et al. Attainment of treatment goals by people with Alzheimer’s disease receiving galantamine: a randomised controlled trial. CMAJ 2006; 174(8): 1099 – 1105.
57. Winblad B, Poritis N. Memantine in severe dementia: Results of the 9M-BEST study (Benefit and efficacy in severely demented patients during treatment with Memantine). International Journal of Geriatric Psychiatry 1999; 14: 135 – 146.
58. Reisberg B, Doody R, Stöffler A et al. Memantine in Moderate-to-Severe Alzheimer’s Disease. NEJM 2003; 348: 1333 – 1341.
59. Tariot PN, Farlow MR, Grossberg GT et al. Memantine treatment in patients with moderate to severe Alzheimer’s disease already receiving donepezil. JAMA 2004; 291: 317 – 324.
60. Pratt RD, Perdomo CA et al. Donepezil-Treated patients with Probable Vascular Dementia Demonstrate Cognitive Benefits. Ann NY Acad Sci 2002; 977: 513 – 522.
61. Black S, Romάn GC, Geldmacher DS et al. Efficacy and Tolerability of Donepezil in Vascular Dementia: Positive Results of a 24-Week, Multicenter, International, Randomized, Placebo-Controlled Clinical Trial. Stroke 2003; 34: 2323 – 2332.
62. Wilkinson D, Dody R, Helme R et al. Donepezil in vascular dementia: A randomised, placebo-controlled study. Neurology 2003; 61: 479 – 486.
63. Erkinjuntti T, Kurz A, Gauthier S et al. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283 – 1290.
64. Bullock R, Erkinjuntti T, Lilienfeld S et al. Management of Patients with Alzheimer’s Disease plus Cerebrovascular Disease: 12-Month Treatment with Galantamine. Dement Geriatr Cogn Disord 2004; 17: 29 – 34.
65. Orgogozo J-M, Rigaud A-S, Stöffler A et al. Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300). Stroke 2002; 33: 1834 – 1839.
66. Wilcock G, Mőbius HJ, Stöffler A et al. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). International Clinical Psychopharmacology 2002; 17: 297 – 305.
67. Salloway S, Ferris S, Kluger A et al. Efficacy of donepezil in mild cognitive impairment. Neurology 2004; 63: 651 – 657.
68. Petersen RC, Thomas RG, Grundman M et al. Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment. NEJM 2005; 352: 2379 – 2388.
69. Koontz J, Baskys A. Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study. American Journal of Alzheimer’s Disease and Other Dementias 2005; 20(5): 295 – 302.
70. Mazza M, Capuano A, Bria P, Mazza S. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer’s dementia in a randomised placebo-controlled double-blind study. European Journal of Neurology 2006; 13: 981 – 985.
71. Black SE, Doody R, Li H et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007; 69: 459 – 469.
72. Feldman HH, Lane R, the Study 304 group. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2007; 78: 1056 – 1063.
73. Mowla A, Mosavinasab M, Haghshenas H, Haghighi AB. Does Seotonin Augmentation Have Any Effect on Cognition and Activities of Daily Living in Alzheimer’s Dementia? A Double-Blind, Placebo-Controlled Clinical Trial. J Clin Psychopharmacol 2007; 27: 484 – 487.
74. Winblad B, Cummings J, Andreasen N et al. A six-month double-blind, randomised, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22: 456 – 467.
75. Bakchine S, Loft H. Memantine Treatment in Patients with Mild to Moderate Alzheimer’s Disease: Results of a Randomised, Double-Blind, Placebo-Controlled 6-Month Study. Journal of Alzheimer’s Disease 2007; 11: 471 – 479.
76. Auchus AP, Brashear HR, Salloway S et al. Galantamine treatment of vascular dementia. Neurology 2007; 69: 448 – 458.
77. Feldman HH, Ferris S, Winblad B et al. Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the InDDEx study. Lancet Neurology 2007; 6: 501 – 512.
78. Van Dyck CH, Tariot PN, Meyers B et al. A 24-week Randomized, Controlled Trial of Memantine in Patients With Moderate-to-severe Alzheimer Disease. Alzheimer Dis Assoc Disord 2007; 21: 136 – 143.
79. Peskind ER, Potkin SG, Pomara N et al. Memantine Treatment in Mild to Moderate Alzheimer Disease : A 24-Week randomized, Controlled Trial. Am J Geriatr Psychiatry 2006; 14: 704 – 715.
80. International Conference on Harmonisation. Structure and Content of clinical study reports, E3, 1995. [http://www.ich.org](http://www.ich.org/)
81. Ritchie CW, Ames D, Clayton T. Meta-analysis of Randomized Trials of the Efficacy and Safety of Donepezil, Galantamine, and Rivastigmine for the Treatment of Alzheimer Disease. Am J Geriatr Psychiatry 2004; 12(4): 358 – 369.

**Table 1: Characteristics of Included Studies (n=57)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **First author & Year of study** | **Countries** | **Study funding source(s)** | **Interventions studied** | **Indication** | **Sample size(s)** | | **Jadad /Schultz Quality Score** |
| **Controls** | **Active Comparators** |
| **Rogers (1996)** | USA | Industry | placebo, donepezil (1, 3, 5mg) | Alzheimer's dementia | 40 | 121 | 4 |
| **Rogers (Arch Intern Med 1998**) | USA | Industry | placebo, donepezil (5, 10mg) | Alzheimer's dementia | 153 | 315 | 4 |
| **Rogers (Neurology 1998)** | USA | Industry | placebo, donepezil (5, 10mg) | Alzheimer's dementia | 162 | 311 | 4 |
| **Aqid (1998)** | Australia, Belgium, Czechoslovakia, Denmark, Finland, France, Germany, Ireland, Norway, Sweden, Switzerland, UK | Industry | Placebo, rivastigmine (4mg, 6mg ) | Alzheimer's dementia | 133 | 269 | 3 |
| **Corey-Bloom (1998)** | USA | Industry | Placebo, rivastigmine (1-4mg, 6-12mg ) | Alzheimer's dementia | 235 | 464 | 5 |
| **Burns (1999)** | Australia, Belgium, Canada, France, Germany, Ireland, New Zealand, South Africa, UK | Industry | placebo, donepezil (5, 10mg) | Alzheimer's dementia | 274 | 544 | 4 |
| **Forette (1999)** | Belgium, Canada, France, Norway, UK | Industry | Placebo, rivastigmine 6 – 9mg (BID, TID) | Alzheimer's dementia | 24 | 90 | 4 |
| **Rösler (1999)** | Australia, France, Germany, Switzerland, USA, Canada | Industry | Placebo, rivastigmine (1-4mg, 6-12mg ) | Alzheimer's dementia | 239 | 486 | 5 |
| **Winblad (1999)** | Latvia | Not reported | placebo, memantine (10mg) | Alzheimer's dementia, Vascular dementia | 84 | 82 | 3 |
| **Greenberg (2000)** | USA | Public | placebo, donepezil (5mg) cross-over trial | Alzheimer's dementia | 30 | 30 | 5 |
| **Homma (2000)** | Japan | Industry | placebo, donepezil (5mg) | Alzheimer's dementia | 129 | 134 | 3 |
| **Kumar (2000)** | USA | Industry (authors employed) | Placebo, rivastigmine (1-4mg, 6-12mg ) | Alzheimer's dementia | 103 | 216 | 3 |
| **Raskind (2000)** | USA | Industry | placebo, galantomine (24, 32mg) | Alzheimer's dementia | 213 | 423 | 5 |
| **Tariot (2000)** | USA | Industry | placebo, galantomine (16,24mg) | Alzheimer's dementia | 286 | 552 | 5 |
| **Wilcock (2000)** | Canada, Finland, France, Germany, Norway, Sweden, Netherlands, UK, | Industry | placebo, galantomine, (24,32mg) | Alzheimer's dementia | 215 | 438 | 5 |
| **Feldman (2001)** | Canada, Australia, France | Industry | placebo, donepezil (5-10mg) | Alzheimer's dementia | 146 | 144 | 5 |
| **Mohs (2001)** | USA | Industry | placebo, donepezil (5-10mg) | Alzheimer's dementia | 217 | 214 | 4 |
| **Tariot (2001)** | USA | Industry | placebo, donepezil (5-10mg) | Alzheimer's dementia | 105 | 103 | 4 |
| **Thomas (2001)** | Italy | Not reported | Donepezil, vitamin E, | Alzheimer's dementia | 20 | 20 | 4 |
| **Winblad (2001)** | Denmark, Finland, Norway, Sweden, Netherlands | Industry | placebo, donepezil (5-10mg) | Alzheimer's dementia | 144 | 142 | 5 |
| **Rockwood (2001)** | USA, Canada, UK, South Africa, Australia, New Zealand | Industry | placebo, galantamine (24-32mg) | Alzheimer's dementia | 125 | 261 | 5 |
| **Wilkinson (2001)** | UK | Industry | placebo, galantamine (18, 24, 36mg) | Alzheimer's dementia | 87 | 198 | 5 |
| **Duraiswamy (2002)** | USA | Industry | placebo, rivastigmine (1-4, 6-12mg) | Alzheimer's dementia | Not reported | Not reported | 3 |
| **Pratt (2002)** | USA, Europe, Canada, Australia | Industry (authors employed) | placebo, donepezil (5, 10mg) | Vascular dementia | 290 | 603 | 5 |
| **Erkinjuntti (2002)** | Canada, Denmark, Finland, France, Germany, Ireland, Israel, Netherlands, Poland, UK | Industry | placebo, 24mg galantamine | Mixed dementia,  Vascular dementia | 196 | 396 | 4 |
| **Orgogozo (2002)** | France, Belgium, Switzerland | Industry | placebo, memantine (20mg) | Vascular dementia | 141 | 147 | 3 |
| **Wilcock (2002)** | UK | Industry (authors employed) | placebo, memantine (20mg) | Vascular dementia | 271 | 277 | 4 |
| **Krishnan (2003)** | USA | Industry | placebo, donepezil (10mg) | Alzheimer's dementia | 33 | 34 | 5 |
| **Tune (2003**) | USA | Industry | placebo, donepezil (10mg) | Alzheimer's dementia | 14 | 14 | 3 |
| **Reisberg (2003)** | USA | Industry, Public | placebo, memantine (20mg) | Alzheimer's dementia | 126 | 126 | 5 |
| **Black (2003)** | USA, UK, Australia, Canada, Germany | Industry | Placebo, donepezil (5, 10mg) | Vascular dementia | 199 | 404 | 5 |
| **Wilkinson (2003)** | USA, Canada, Australia, Europe | Industry | Placebo, donepezil (5, 10mg) | Vascular dementia | 193 | 423 | 5 |
| **AD 2000 Collaborative Group (2004)** | UK | Public | Placebo, donepezil (5-10mg) | Alzheimer's dementia | 244  Phase 1 | 242  Phase 1 | 4 |
| **Holmes (2004)** | UK | Industry | Placebo, donepezil (10mg) | Alzheimer's dementia | 55 | 41 | 5 |
| **Seltzer (2004)** | USA | Industry | Placebo, donepezil (10mg) | Alzheimer's dementia | 57 | 96 | 4 |
| **Tariot (2004)** | USA | Industry | placebo, memantine (20mg) | Alzheimer's dementia already on donepezil | 201 | 202 | 5 |
| **Bullock (2004)** | Canada, Denmark, Finland, France, Germany, Israel, Netherlands, Poland, UK | Industry (authors employed) | Placebo, galantamine (24mg) | Mixed dementia | 97 | 188 | 4 |
| **Salloway (2004)** | USA | Industry | Placebo, donepezil (10mg) | Mild cognitive impairment | 137 | 133 | 4 |
| **Karaman (2005)** | Turkey | Not reported | placebo,  rivastigmine (6-12mg) | Alzheimer's dementia | 20 | 24 | 4 |
| **Bullock (2005)** | Australia, Canada, France, Germany, Italy, Spain, UK | Industry | 3-12mg of rivastigmine, 5-10mg donepezil | Alzheimer’s dementia | 499  donepezil | 495  rivastigmine | 5 |
| **Broduty (2005)** | USA, Australia, Canada, South Africa, New Zealand | Industry (authors employed) | placebo, immediate release galantamine (16-24mg), prolonged release galantamine (16-24mg) | Alzheimer's dementia | 324 | 647 | 5 |
| **Peterson (2005)** | USA, Canada | Industry,  Public | placebo, donepezil (10mg) | Mild cognitive impairment | 259 | 253 | 4 |
| **Koontz (2005)** | USA | Industry | placebo, galantamine (24mg) | Mild cognitive impairment | 11 | 8 | 4 |
| **Dos Santos Moraes (2006)** | Brazil | Public | Placebo, donepezil (10mg) | Alzheimer's dementia | 18 | 17 | 4 |
| **Johannsen (2006)** | Belgium, Denmark, Germany, Greece, Hungary, Iceland, Netherlands, Poland, USA | Industry | Placebo, donepezil (10mg) | Alzheimer's dementia | 103 | 99 | 4 |
| **Winblad (2006)** | Sweden | Industry | Placebo, donepezil (5-10mg) | Alzheimer's dementia | 120 | 128 | 5 |
| **Rockwood (2006)** | Canada | Industry,  Public | Placebo, galantamine  (16-24mg) | Alzheimer's dementia | 66 | 64 | 5 |
| **Mazza**  **(2006)** | Not reported (likely Italy) | Not reported | Placebo, donepezil (5mg), Ginkgo | Alzheimer's dementia | 26 | 25 | 5 |
| **Peskind**  **(2006)** | USA | Industry | Placebo, memantine (20mg) | Alzheimer's dementia | 202 | 201 | 5 |
| **Auchus**  **(2007)** | 21 countries (Europe, North America, Israel, Asia, Australia) | Industry  (authors employed) | Placebo, galantamine (flexible dose) | Vascular dementia | 391 | 397 | 4 |
| **Bakchine**  **(2007)** | Austria, Belgium, Denmark, Finland, France, Greece, Lithuania, The Netherlands, Poland, Spain, Sweden, UK | Industry | Placebo, memantine (20mg) | Alzheimer's dementia | 152 | 318 | 4 |
| **Black**  **(2007)** | USA, Canada, France, UK, Australia | Industry | Placebo, donepezil (10mg) | Alzheimer's dementia | 167 | 176 | 5 |
| **Feldman (Lancet Neurol 2007)** | 14 countries | Industry | Placebo, rivastigmine (3 – 12mg) | Mild cognitive impairment | 509 | 508 | 5 |
| **Feldman**  **(J Neurol Neurosurg Psychiatry 2007)** | Australia, Canada, Ireland, Italy, South Africa, UK | Industry | Placebo, rivastigmine 2 – 12 mg BID vs. TID dosing | Alzheimer's dementia | 222 | 229 BID group  227 TID group | 5 |
| **Mowla**  **(2007)** | Not reported (likely Iran) | Public | Placebo, rivastigmine 6 – 12mg, rivastigmine 6 – 12mg + fluoxetine | Alzheimer's dementia | 40 | 41 rivastigmine alone | 4 |
| **Van Dyck**  **(2007)** | USA | Industry | Placebo, memantine (20mg) | Alzheimer's dementia | 172 | 178 | 5 |
| **Winblad**  **(2007)** | 21 countries | Industry | Placebo, 10 cm2 rivastigmine patch, 20 cm2 rivastigmine patch, 12mg rivastigmine tablet | Alzheimer's dementia | 302 | 293 (10 cm2 patch)  303 (20 cm2 patch)  297 (12mg tablet) | 5 |

# Table 2: Types of ITT and non-ITT analyses employed and number of contraindications to Last Observation Carried Forward (LOCF)

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study**  **(Author, Journal)** | **Number of contraindications to the use of LOCF** | | | | **Type of ITT analysis performed** | Non-ITT analyses indicated | Only performed  non-ITT analysis  OR  Type of ITT analysis not specified | LOCF is only form of ITT analysis  +  Explicitly demonstrates factors that can introduce bias in favor of the study drug in LOCF analysis |
| **Greater dropout rate in treatment group?**  **(if yes,**  **dropout rates provided)** | **Earlier dropouts in treatment group?** | **More rapid progressors in treatment dropout group?** | **TOTAL number of contraindication to the use of LOCF** |  |  |  |  |
| **Donepezil in Alzheimer’s Dementia** | | | | | | | | |
| Rogers 1996 | No | Not ruled out | Not ruled out | 0 - 2 | LOCF described although the term ‘LOCF’ not explicitly used | None |  |  |
| Rogers  Arch Intern Med 1998 | Yes Placebo 7%  5mg 10% 10mg 18% | Not ruled out | Not ruled out | 1 - 3 | LOCF | FEP |  | **+** |
| Rogers  Neurology 1998 | **Yes**  Placebo 20%  5mg 15%  10mg 32% | Not ruled out | Not ruled out | 1 - 3 | LOCF | FEP |  | **+** |
| Burns 1999 | **Yes**  Placebo 20%  5mg 22%10mg 26% | Not ruled out | Not ruled out | 1 - 3 | LOCF | FEP,  OCA,  Retrieved Dropout |  | **+** |
| Greenberg 2000 | Yes Placebo 5%  5mg 10% | Not ruled out | Not ruled out | 1 - 3 | Type of ITT analysis not specified | Type of analysis not specified | **+** |  |
| Homma 2000 | No | Not ruled out | Not ruled out | 0 - 2 | Type of ITT analysis not specified | TPP | **+** |  |
| Feldman 2001 | No | No | Not ruled out | 0 - 1 | LOCF | OCA |  |  |
| Mohs 2001 | No | Not ruled out | Not ruled out | 0 - 2 | LOCF | OCA |  |  |
| Tariot 2001 | No | Not ruled out | Not ruled out | 0 - 2 | LOCF | OCA |  |  |
| Thomas 2001 | No | No | No | 0 | No ITT analysis performed | CA | **+** |  |
| Winblad 2001 | No | No | Not ruled out | 0 - 1 | LOCF | OCA |  |  |
| Krishnan 2003 | No | Not ruled out | Not ruled out | 0 - 2 | LOCF | OCA |  |  |
| Tune 2003 | No | Not ruled out | Not ruled out | 0 - 2 | Type of ITT analysis not specified | Type of analysis not specified | **+** |  |
| AD2000 Collaborative Group, 2004;  ***(Alzheimer’s and Mixed dementia)*** | No | Not ruled out | Yes | 1 - 2 | Most recent previous score was used (similar to LOCF), if one existed; if not, then the next subsequent valid score was substituted | None |  | **+** |
| Holmes 2004 | No | Not ruled out | Yes | 1 - 2 | LOCF | OCA |  | **+** |
| dos Santos Moraes 2006 | No | No | No | 0 | Type of ITT analysis not specified | Type of analysis not specified | **+** |  |
| Seltzer 2004 | Yes Placebo 19% 10mg 27% | Not ruled out | Not ruled out | 1 - 3 | LOCF | FEP |  | **+** |
| Johannsen 2006 | No | Not ruled out | Not ruled out | 0 - 2 | LOCF | OCA |  |  |
| Winblad 2006 | Yes Placebo 18% 5/10mg 26% | Not ruled out | Not ruled out | 1 - 3 | LOCF, **Modelling - replaced missing data with the mean of the observed values for the change from baseline to month 6 in the placebo group**  **(LOCF and Modelling provided similar point estimates in SIB, ADCS-ADL-severe, CGI-I, MMSE, NPI)** | CA |  |  |
| Mazza 2006 | No | Not ruled out | Not ruled out | 0 - 2 | Type of ITT analysis not specified |  | **+** |  |
| Black 2007 | Yes Placebo 24%  10mg 34% | Not ruled out | Not ruled out | 1 - 3 | LOCF | OCA |  | **+** |
| **Rivastigmine in Alzheimer’s dementia** | | | | | | | | |
| Agid 1998 | Yes Placebo 6% 4mg 12% 6mg 15% | Not ruled out | Not ruled out | 1 - 3 | No ITT analysis performed | OCA | **+** |  |
| Corey-Bloom 1998 | Yes Placebo 7% 1-4mg 15% 6-12mg 35% | Yes | Not ruled out | 2 - 3 | LOCF | OCA |  | **+** |
| Forette 1999 | Yes Placebo 21%  6 – 9mg via bid dosing 50%  6 – 9mg via tid dosing  38% | Not ruled out | Not ruled out | 1 - 3 | No ITT analysis performed | FEP | **+** |  |
| Rösler 1999 | Yes Placebo 13%  1-4 mg 14% 6–12mg 32% | Yes | Not ruled out | 2 - 3 | LOCF | OCA |  | **+** |
| Kumar 2000 | Yes Placebo 16% 1–4 mg 14% 6–12mg 33% | Not ruled out | Not ruled out | 1 - 3 | No ITT analysis performed | OCA | **+** |  |
| Doraiswamy 2002 | Not ruled out | Not ruled out | Not ruled out | 0 - 3 | LOCF | OCA |  |  |
| Karaman 2005 | Yes Placebo 0%  6–12mg 13% | No | No | 1 | No ITT analysis performed | OCA | **+** |  |
| Bullock 2005 ***(Rivastigmine vs. Donepezil)*** | Yes Donepezil  5–10mg 36%  Rivastigmine 3–12mg 47% | Yes | Not ruled out | 2 - 3 | LOCF | OCA, FEP |  | **+** |
| Feldman 2007  J Neurol Neurosurg Psychiatry | Yes Placebo 15%  Riv bid 24%  Riv tid 17% | Not ruled out | Not ruled out | 1 - 3 | LOCF | OCA.  Retrieved dropout + LOCF |  | **+** |
| Mowla 2007 | No | Not ruled out | Not ruled out | 0 - 2 | Type of analysis not specified | Type of analysis not specified | **+** |  |
| Winblad 2007 | Yes Placebo 12%  10cm2 22%  20cm2 21%  12mg 22% | Not ruled out | Not ruled out | 1 - 3 | LOCF | OCA  Retrieved dropout |  | **+** |
| **Galantamine in Alzheimer’s Dementia** | | | | | | | | |
| Raskind 2000 | Yes Placebo 9% 24 mg 32%  32 mg 42% | Not ruled out | Not ruled out | 1 - 3 | LOCF, **The time response relationship for change in ADAScog/11 was analysed using generalized linear interactive modelling (results of modelling not provided)** | OCA |  |  |
| Tariot 2000 | Yes Placebo 16% 8 mg 23%  16mg 22%  24 mg 22% | Not ruled out | Not ruled out | 1 - 3 | LOCF | OCA |  | **+** |
| Wilcock 2000 | Yes Placebo 13%  24mg 20%  32mg 25% | Not ruled out | Not ruled out | 1 - 3 | Term LOCF not employed but technique described in paper,  **The time response relationship for change in ADAScog/11 was analysed using generalized linear mixed modelling**  **(results of modelling not provided)** | OCA |  |  |
| Rockwood 2001 | Yes Placebo 11%  24 or 32mg 33% | Not ruled out | Not ruled out | 1 - 3 | LOCF | OCA |  | **+** |
| Wilkinson 2001 | Yes Placebo 16%  18 mg 28%  24 mg 28%  36 mg 48% | Not ruled out | Not ruled out | 1 - 3 | LOCF | TPP |  | **+** |
| Brodaty 2005 | Yes Placebo 23%  Galantamine immediate release 31%  Galantamine Prolonged Release 25% | Not ruled out | Not ruled out | 1 - 3 | LOCF | OCA |  | **+** |
| Rockwood 2006 | No | Not ruled out | Not ruled out | 0 - 2 | LOCF , **Mixed effects modelling**  **(point estimates of outcomes based on modelling not provided)** | OCA |  |  |
| **Memantine In Alzheimer’s Dementia** | | | | | | | | |
| ***Winblad 1999***  ***(both Alzheimer’s and Vascular dementia studied)*** | No | Not ruled out | Not ruled out | 0 - 2 | **Missing endpoint data replaced by worst ranks** | TPP |  |  |
| Reisberg 2003 | No | Not ruled out | Not ruled out | 0 - 2 | LOCF, **Replaced missing values with mean observed value for decline in placebo group**  **(point estimates of outcomes based on modelling not provided)** | OCA |  |  |
| Tariot 2004 | No | Not ruled out | Not ruled out | 0 - 2 | LOCF | OCA |  |  |
| Peskind 2006 | No | Not ruled out | Not ruled out | 0 - 2 | LOCF,  Mixed models repeated measures (MMRM)  **(point estimates of outcomes based on modelling not provided)** | OCA |  |  |
| Bakchine 2007 | Yes  Placebo 11%  20mg 16% | Not ruled out | Not ruled out | 1 - 3 | LOCF mentioned but results not provided | CA, OCA | **+** |  |
| Van Dyck 2007 | No | Not ruled out | Not ruled out | 0 - 2 | LOCF,  Mixed models repeated measures (MMRM)  **(point estimates of outcomes based on modelling not provided)** | OCA |  |  |
| **Donepezil** in Vascular Dementia and Mixed Dementia | | | | | | | | |
| Pratt 2002 | Yes Placebo 15%  5 mg 18%  10 mg 29% | Not ruled out | Not ruled out | 1 - 3 | LOCF | OCA |  | **+** |
| Black 2003 | Yes Placebo 15%  5 mg 19%  10 mg 28% | Not ruled out | Not ruled out | 1 - 3 | LOCF | OCA |  | **+** |
| Wilkinson 2003 | Yes Placebo 17%  5 mg 19%  10 mg 25% | Yes | Not ruled out | 2 - 3 | LOCF | OCA |  | **+** |
| **Galantamine** in Vascular Dementia and Mixed Dementia | | | | | | | | |
| Erkinjuntti 2002 | Yes Placebo 15%  24 mg 26% | Yes | Not ruled out | 2 - 3 | LOCF,  Mixed Effects model **(results of modelling not provided)** | OCA |  | **+** |
| Bullock 2004 | Yes Placebo 14%  24 mg 22% | Not ruled out | Not ruled out | 1 - 3 | Used term ‘Observed Case analysis’ but describe LOCF | None |  | **+** |
| Auchus 2007 | Yes Placebo 15%  8-24mg 24% | Not ruled out | Not ruled out | 1 - 3 | LOCF | OCA |  | **+** |
| **Memantine** in Vascular Dementia and Mixed Dementia | | | | | | | | |
| Orgogozo 2002 | Yes Placebo 16%  20 mg 21% | Not ruled out | Not ruled out | 1 - 3 | LOCF | OCA, TPP |  | **+** |
| Wilcock 2002 | No | Not ruled out | Not ruled out | 0 - 2 | LOCF | TPP |  |  |
| **Donepezil** in Mild Cognitive Impairment (MCI) | | | | | | | | |
| Salloway 2004 | Yes Placebo 17%  10 mg 32% | Not ruled out | Not ruled out | 1 - 3 | LOCF | OCA, FEP |  | **+** |
| Petersen 2005 | Yes Placebo 25%  10 mg 36% | Yes | Yes | 3 | **Employed a sensitivity analysis consisting of a number of simulations (modelling)** | **For secondary outcomes “missing values were imputed with the use of a projection method appropriate for assessing responses among subjects with neurodegenerative diseases.”** |  |  |
| **Galantamine** in Mild Cognitive Impairment (MCI) | | | | | | | | |
| Koontz 2005 | Yes Placebo 36%  24 mg 50% | Not ruled out | Not ruled out | 1 - 3 | Type of analysis not specified | Description suggests OCA | **+** |  |
| **Rivastigmine** in Mild Cognitive Impairment (MCI) | | | | | | | | |
| Feldman 2007  Lancet Neurology | No | Not ruled out | Not ruled out | 0 - 3 | LOCF described although the term ‘LOCF’ not explicitly used | OCA |  |  |

**Abbreviations: LOCF = Last Observation Carried Forward; FEP = Fully Evaluable Population analysis; CA = Completer Analysis; TPP = Treatment Per Protocol analysis; ATA = As Treated Analysis; OCA = Observed Case Analysis; SIB = Severe Impairment Battery; ADCS-ADL-severe = the Modified Alzheimer’s Disease Cooperative Study activities of daily living inventory for severe Alzheimer’s disease; CGI-I = Clinical Global Impression of Improvement; MMSE = Mini-mental State Examination; NPI = Neuropsychiatric Inventory.**

**Table 3: Type of Efficacy Analysis Used/Described**

|  |  |
| --- | --- |
| **Characteristic** | **Frequency (% of total)**  **Some studies employed > one technique in each category** |
| **Use of ITT principle**  ***# that indicated use of an ITT analysis***  ***Last Observation Carried Forward ( LOCF)***  ***Modeling (results provided)*** | 45/57 (79 %)  42/57 (74 %)  **9/57 (16 %)** |
| **Use of non-ITT techniques\*\***  Observed Case Analysis (OCA)  Fully Evaluable Population analysis (FEP)  Treatment Per Protocol analysis (TPP)  Completer Analysis (CA) | 44/57 (77 %)  35/57 (61 %)  5/57 (9 %)  5/57 (9 %)  3/57 (5 %) |
| **Discussion of data analysis issues**  # mentioning importance of missing data  # discussing limits of LOCF or non-ITT analysis | 10/57 (18 %)  7/57 (12 %) |

\*note that studies may have used more than one approach

**Table 4: Account of Dropouts by Drug Class**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Cholinesterase Inhibitors**  **(n=49 studies)** | | **Memantine**  **(n=8 studies)** | |
|  | |  | |
| **Description of drop-outs**  # that described total study drop-outs  # studies with larger dropout in experimental group  # studies with larger dropout in control group  Similar dropout rates between groups | 46/49 (94 %)  **36/49 (73 %)**  **8/49 (16 %)**  **2/49 (4 %)** | | 8/8 (100 %)  **2/8 (25 %)**  **2/8 (25 %)**  **4/8 (50 %)** | |
| **Timing of dropouts**  # of articles describing drop-out timing | 7/49 (14 %) | | 0/8 (0 %) | |
|  |  |  |  |  |
|  | **Control**  **Group**  **N = 7275** | **Experimental**  **Groups**  **N = 11969** | **Control**  **Group**  **N = 1349** | **Experimental**  **Groups**  **N = 1539** |
| # completing study | 6050 | 9198 | 1099 | 1315 |
| DROPOUT RATE | **16.8 %** | **23.2 %** | **18.5 %** | **14.6 %** |